NEW YORK (CNN/Money) - A federal grand jury is seeking information about Pfizer Inc.'s diabetes drug Rezulin, which was pulled from the market in 2000.

Pfizer (PFE: Research, Estimates), in a filing with the Securities and Exchange Commission Thursday, said a federal grand jury in Maryland is seeking documents relating to Rezulin and testimony from former employees of its subsidiary Warner-Lambert.

The company said it is cooperating with the investigation.

Rezulin was withdrawn on concern it was linked with liver damage; the company is facing more than 2,000 federal and state lawsuits.

Pfizer also said the Department of Justice is probing two years of the company's pricing of Lipitor, which is used to treat high cholesterol.

The investigation is centered on whether grants made to certain health plans and pharmacy benefit managers should be characterized as rebates, Pfizer said in an annual report filed with the U.S. Securities and Exchange Commission.

Related Stories       Pfizer repeats guidance - March 21, 2002

Rebates would entitle the U.S. government to a better discount under Medicaid price rules, the New York-based company added.

Pfizer said it was cooperating with the investigation on 1999 and 2000 pricing by Warner-Lambert, which Pfizer bought in June 2000.  

-- from staff and wire reports